Fortrea Holdings (FTRE) Revenue (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Revenue came in at $678.2 million in Q2 2026, down 4.52% YoY from $710.3 million in Q2 2025, and up 6.55% on a QoQ basis from $636.5 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Revenue data on file, last reported at $678.2 million in Q2 2026.
- Quarterly Revenue fell 4.52% year-over-year to $678.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.7 billion (down 2.09% YoY) and the FY2025 annual result came in at $2.7 billion, up 1.0% from the prior year.
- Revenue rose to $678.2 million in Q2 2026, from $636.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $793.1 million in Q2 2022 to a low of $502.6 million in Q4 2022.
- A 5-year average of $684.4 million and a median of $693.9 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue surged 41.21% — and 2024, when it dropped 8.65%.
- Tracing FTRE's Revenue over 5 years: stood at $502.6 million in 2022, then surged by 41.21% to $709.7 million in 2023, then slipped by 1.79% to $697.0 million in 2024, then dropped by 5.24% to $660.5 million in 2025, then climbed by 2.68% to $678.2 million in 2026.
- The last three Revenue figures came in at $678.2 million (Q2 2026), $636.5 million (Q1 2026), and $660.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | 678.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 678.20 Mn |
| Mar 31, 2026 | 636.50 Mn |
| Dec 31, 2025 | 660.50 Mn |
| Sep 30, 2025 | 701.30 Mn |
| Jun 30, 2025 | 710.30 Mn |
| Mar 31, 2025 | 651.30 Mn |
| Dec 31, 2024 | 697.00 Mn |
| Sep 30, 2024 | 674.90 Mn |
| Jun 30, 2024 | 662.40 Mn |
| Mar 31, 2024 | 662.10 Mn |
| Dec 31, 2023 | 709.70 Mn |
| Sep 30, 2023 | 713.80 Mn |
| Jun 30, 2023 | 725.10 Mn |
| Mar 31, 2023 | 693.90 Mn |
| Dec 31, 2022 | 502.60 Mn |
| Sep 30, 2022 | 762.30 Mn |
| Jun 30, 2022 | 793.10 Mn |